CRISPR Therapeutics AG Aktie News

-Daten in einer Late‑Breaking‑Präsentation auf dem European Society of Cardiology (ESC) Congress 2026 vorgestellt- -Phase‑1a‑Klinikdaten für CTX310® zeigten weiterhin robuste, dosisabhängige Reduktionen des zirkulierenden ANGPTL3 mit einer mittleren Reduktion gegenüber Basiswert von 79 % (maximal 89 %), einer mittleren Reduktion der Triglyceride (TG) von 48 % (maximal 78 %) und einer mittleren ...

ZUG, Switzerland und BOSTON, 03. Aug. 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) berichtete heute über die Finanzergebnisse für das am 30. Juni 2026 endende zweite Quartal.

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Global Healthcare Conference Date: Wednesday, June 3, 2026Time: 9:55 a.m.

ZUG, Switzerland and BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will present at the Bank of America Securities 2026 Global Healthcare Conference on Tuesday, May 12, 2026 1:40 p.m. PDT.

ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026.

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.

CEO Eric Lefkofsky framed the trajectory plainly: “As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world.